n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company that is developing innovative immunomodulation treatments through novel drug delivery routes, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will be presenting at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will focus primarily on recent clinical updates of intranasal foralumab. a fully human anti-CD3 monoclonal antibody, intended for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s disease. Tiziana’s control will also participate in individual conference meetings.
Presentation Information
Presenter: Matthew Davis, MD, RPh. , Chief Operating Officer and Chief Medical Officer, Tiziana Life Sciences Title: Intranasal Anti-CD3 mAb Treatment to Enable Advances in Neuroinflammatory and Neurodegenerative Diseases
Date: Wednesday, November 8 Time: 10:00 – 10:15 CET Place: Sala San Sebastián
BIO-Europe brings together more than 5,500 participants, representing 60 countries and more than 2,220 companies, making the occasion the largest gathering of biopharmaceutical professionals in Europe.
About Foralumab
Activated T-mobiles play a vital role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T-mobile receptor and attenuates inflammation by modulating T-mobile function, thereby suppressing effector features in several immune motile subsets. This effect has been demonstrated in COVID and multiple sclerosis patients, as well as normal, healthy subjects. The Phase 2 trial of non-active intranasal foralumab SPMS is expected to begin detection in November 2023. Immunomodulation of nasal anti-CD3 mAb represents a new avenue for the remedy of human neuroinflammatory and neurodegenerative diseases. 1,2
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing innovative treatments that employ transformative drug delivery technologies to enable select immunotherapy pathways. Tiziana’s state-of-the-art nasal technique has prospects for efficacy as well as protection and tolerability compared to intravenous (IV) administration. Tiziana’s lead candidate, intranasal foralombab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable protection profile and clinical reaction in patients in studies to date. Tiziana’s generation for immunotherapy pathways of choice has been patented with several pending programs and is expected to allow for extensive programs in the pipeline.
For any additional requests:
Tiziana Life Sciences Ltd.
Paul Spencer, Business Development & Investor Relations (0) 207 495 2379 Email: info@tizianalifesciences. com
Investors: Irina KofflerLifeSci Advisors, LLC 4681ikoffler@lifesciadvisors. com 1,646,970
_________________
1 https://www. pnas. org/doi/10. 1073/pnas. 22202721202 https://www. pnas. org/doi/10. 1073/pnas. 2309221120